Medicine and Media: The Ranitidine Debate

Ranitidine has been the topic of recent media reports. Current findings, confirmed by the US Food and Drug Administration, indicate that some ranitidine products contain a substance that may be carcinogenic. Providers and patients require additional information on the risks of continuing therapy vs....

Descripción completa

Detalles Bibliográficos
Autores principales: Wagner, Jennifer A., Colombo, Jennifer M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359940/
https://www.ncbi.nlm.nih.gov/pubmed/32107850
http://dx.doi.org/10.1111/cts.12753
Descripción
Sumario:Ranitidine has been the topic of recent media reports. Current findings, confirmed by the US Food and Drug Administration, indicate that some ranitidine products contain a substance that may be carcinogenic. Providers and patients require additional information on the risks of continuing therapy vs. the benefits of the medication. This article comments on what is currently known about the evolving situation of elevated N‐nitrosodimethylamine levels in ranitidine and the limits of the existing information to assess best practices.

Ejemplares similares